A First Cost-Effectiveness Analysis Based on Real Life Clinical Outcomes of Bevacizumab+ Paclitaxel Compared to Paclitaxel Among French Patients with HER2- Metastatic Breast Cancer in First Line of Treatment

Cost Effectiveness ◽

Clinical Outcomes ◽

Real Life ◽

Metastatic Breast ◽

First Line ◽

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

First Line ◽

Hormone Receptor Positive ◽

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

ClinicoEconomics and Outcomes Research ◽

10.2147/ceor.s178934 ◽

2018 ◽

Vol Volume 10 ◽

pp. 773-790 ◽

Cited By ~ 7

Author(s):

Elena Galve-Calvo ◽

Eva González-Haba ◽

Joana Gostkorzewicz ◽

Irene Martínez ◽

Alejandro Pérez-Mitru

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

BMC Cancer ◽

10.1186/s12885-017-3774-7 ◽

2017 ◽

Vol 17 (1) ◽

Author(s):

Takeru Shiroiwa ◽

Takashi Fukuda ◽

Kojiro Shimozuma ◽

Mitsuko Mouri ◽

Yasuhiro Hagiwara ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Treatment ◽

Metastatic Breast ◽

Breast Cancer Treatment ◽

Phase Iii ◽

First Line ◽

PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination

Value in Health ◽

10.1016/j.jval.2020.08.206 ◽

2020 ◽

Vol 23 ◽

pp. S433-S434

Author(s):

G. Vondeling ◽

E. Palaka ◽

C. Livings ◽

J. Naik ◽

W. Sullivan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Novel Therapies ◽

Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-3107-3 ◽

2014 ◽

Vol 147 (2) ◽

pp. 443-443 ◽

Cited By ~ 1

Author(s):

Vakaramoko Diaby ◽

Georges Adunlin ◽

Simon B. Zeichner ◽

Kiran Avancha ◽

Gilberto Lopes ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Hormone Receptor ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Cost-Effectiveness Analysis of Fulvestrant in the Treatment of Metastatic Breast Cancer in Second-Line Chemotherapy

Value in Health ◽

10.1016/j.jval.2014.08.2289 ◽

2014 ◽

Vol 17 (7) ◽

pp. A637

Author(s):

I. Krysanov ◽

V. Krysanova

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Second Line ◽

Second Line Chemotherapy ◽

Effectiveness Analysis ◽

Line Chemotherapy

Cost-effectiveness analysis of routine use of eribulin in patients with metastatic breast cancer in France: A retrospective analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e11531 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e11531-e11531

Author(s):

Marie-Justine Paillard ◽

Elsa Curtit ◽

Virginie Nerich ◽

Laurent Cals ◽

Fernando Bazan ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Retrospective Analysis ◽

Metastatic Breast ◽

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.567 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 567-567 ◽

Cited By ~ 3

Author(s):

Klazien Matter-Walstra ◽

Matthias Schwenkglenks ◽

Peter Brauchli ◽

Dirk Klingbiel ◽

Konstantin J. Dedes

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

Estrogen Receptor Positive ◽

First Line Treatment

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer In Spain: Management in the Later Lines of Therapy

Value in Health ◽

10.1016/j.jval.2015.03.1175 ◽

2015 ◽

Vol 18 (3) ◽

pp. A203 ◽

Cited By ~ 1

Author(s):

U. Majethia ◽

G. Tremblay ◽

I. Kontoudis ◽

J. DeRosendo

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Eribulin Mesylate ◽

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

The Breast ◽

10.1016/j.breast.2019.11.012 ◽

2020 ◽

Vol 49 ◽

pp. 141-148 ◽

Cited By ~ 2

Author(s):

Vakaramoko Diaby ◽

Hussain Alqhtani ◽

Sascha van Boemmel-Wegmann ◽

Ching-Yu Wang ◽

Askal Ayalew Ali ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Effectiveness Analysis ◽

Her 2 ◽

Treatment Sequences